NASDAQ: CBUS
Cibus Inc Stock

$1.98-0.11 (-5.26%)
Updated Mar 26, 2025
CBUS Price
$1.98
Fair Value Price
-$0.01
Market Cap
$68.01M
52 Week Low
$1.80
52 Week High
$22.99
P/E
-0.18x
P/B
0.74x
P/S
15.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.26M
Earnings
-$251.39M
Gross Margin
100%
Operating Margin
-5,095.47%
Profit Margin
-5,898.4%
Debt to Equity
2.74
Operating Cash Flow
-$58M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CBUS Overview

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CBUS's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CBUS
Ranked
#428 of 479

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CBUS news, forecast changes, insider trades & much more!

CBUS News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CBUS ($1.98) is overvalued by 29,761.41% relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CBUS ($1.98) is not significantly undervalued (29,761.41%) relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CBUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CBUS due diligence checks available for Premium users.

Valuation

CBUS fair value

Fair Value of CBUS stock based on Discounted Cash Flow (DCF)

Price
$1.98
Fair Value
-$0.01
Undervalued by
29,761.41%
CBUS ($1.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBUS ($1.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CBUS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.18x
Industry
-115.59x
Market
31.65x

CBUS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.74x
Industry
4.53x
CBUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CBUS's financial health

Profit margin

Revenue
$1.2M
Net Income
-$23.1M
Profit Margin
-1,906.1%
CBUS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CBUS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$350.1M
Liabilities
$252.2M
Debt to equity
2.74
CBUS's short-term liabilities ($19.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBUS's long-term liabilities ($232.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.0M
Investing
-$56.0k
Financing
-$306.0k
CBUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CBUS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CBUSF$68.01M-5.26%-0.18x0.74x
IMABC$68.11M-3.91%N/A0.31x
EPIXD$67.91M-1.29%-2.22x0.57x
ANROD$67.68M-1.19%-1.00x0.45x
CRVOF$67.10M-12.88%-3.82x1.71x

Cibus Stock FAQ

What is Cibus's quote symbol?

(NASDAQ: CBUS) Cibus trades on the NASDAQ under the ticker symbol CBUS. Cibus stock quotes can also be displayed as NASDAQ: CBUS.

If you're new to stock investing, here's how to buy Cibus stock.

What is the 52 week high and low for Cibus (NASDAQ: CBUS)?

(NASDAQ: CBUS) Cibus's 52-week high was $22.99, and its 52-week low was $1.80. It is currently -91.39% from its 52-week high and 9.76% from its 52-week low.

How much is Cibus stock worth today?

(NASDAQ: CBUS) Cibus currently has 34,350,784 outstanding shares. With Cibus stock trading at $1.98 per share, the total value of Cibus stock (market capitalization) is $68.01M.

Cibus stock was originally listed at a price of $562.50 in Jul 20, 2017. If you had invested in Cibus stock at $562.50, your return over the last 7 years would have been -99.65%, for an annualized return of -55.38% (not including any dividends or dividend reinvestments).

How much is Cibus's stock price per share?

(NASDAQ: CBUS) Cibus stock price per share is $1.98 today (as of Mar 26, 2025).

What is Cibus's Market Cap?

(NASDAQ: CBUS) Cibus's market cap is $68.01M, as of Mar 28, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cibus's market cap is calculated by multiplying CBUS's current stock price of $1.98 by CBUS's total outstanding shares of 34,350,784.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.